ZMS-2195
/ Simcere
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
A novel highly potent multiple-RAS inhibitor ZMS-2195 efficiently blocks MAPK pathway activation and induces robust anti-tumor growth effects in preclinical models
(AACR 2026)
- "At a dose of 0.8 mg/kg, ZMS-2195 induced tumor regression in PK59 (KRASG12D/WT, PDAC) xenograft model. In summary, ZMS-2159 is a potent Multi-RAS inhibitor with robust activity against RAS-driven tumor cells, supporting its further development as a target therapy for cancers driven by diverse RAS aberrations."
Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BRAF • DUSP6 • HRAS • KRAS • NRAS
1 to 1
Of
1
Go to page
1